Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00079495 | Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS) | PHASE2 | COMPLETED | 150 | — | — | Jul 1, 2003 | Apr 1, 2005 | Mar 21, 2008 | - | — |
| Name | Type | Description |
|---|---|---|
| NBI-5788 | DRUG | - |
Inclusion Criteria: * Male or female, 18 to 55 years of age * Diagnosed with relapsing multiple sclerosis, with at least one relapse in the last two years * Females must not plan on becoming pregnant * Females must either be post-menopausal, surgically incapable of bearing children, or practicing a...